Search
Now showing items 1-6 of 6
Blunted neuro-endocrine responses linking depressive symptoms and ECG left ventricular hypertrophy in black Africans: the SABPA study
(Wolters Kluwer, 2014)
Objective: Chronic psychosocial stress as experienced in an urban environment plays an important role in the aetiology of depression-related cardiovascular risk. It is uncertain whether acute mental stress responses aggravate ...
The interactions of azure B, a metabolite of methylene blue, with 2 acetylcholinesterase and butyrylcholinesterase
(Elsevier, 2014)
Methylene blue(MB) is reported to possess diverse pharmacological actions and is attracting increasing attention
for the treatment of neurodegenerative disorders such as Alzheimer's disease. Among the pharmacological
actions ...
Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries
(Sage, 2014)
Objective: Whilst dopaminergic dysfunction remains a necessary component involved in the pathogenesis of schizophrenia,
our current pharmacological armoury of dopamine antagonists does little to control the negative ...
A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia
(Elsevier, 2014)
Background: While antipsychotics are effective in the maintenance treatment of schizophrenia they have
safety and tolerability risks. We investigated whether a combination of omega-3 polyunsaturated fatty acids
(ω−3 ...
Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties
(Elsevier, 2014)
Aims: The phenothiazinium compound, methylene blue (MB), possesses diverse pharmacological actions and is
attracting attention for the treatment of bipolar disorder and Alzheimer's disease. MB acts on both monoamine
oxidase ...
New insights on the antidepressant discontinuation syndrome
(Wiley, 2014)
Objective Antidepressants are at best 50–55% effective. Non-compliance and the antidepressant discontinuation syndrome (ADS) are
causally related yet poorly appreciated. While ADS is associated with most antidepressants, ...